Madrigal Pharmaceuticals, Inc. (MDGL) Cash Flow Statement
Madrigal Pharmaceuticals, Inc. (MDGL) generated -$197.7M of operating cash flow over the twelve months to 2026-06-30, spent $8.6M on capital expenditure and had free cash flow of -$206.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MDGLMadrigal Pharmaceuticals, Inc.Follow MDGL — free
—
Price chart with a free account
- Market cap
- 10.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2012 Dec 12 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -0.05 | -0.46 | -0.19 | -0.20 | |
| Capital expenditure | 0.00 | 0.00 | 0.00 | -0.01 | |
| Free cash flow | -0.05 | -0.46 | -0.19 | -0.21 | |
| Share repurchases | 0.00 | — | — | — | |
| Stock-based compensation | 0.00 | 0.08 | 0.10 | — |
USD billions · SEC XBRL
Madrigal Pharmaceuticals, Inc. — questions
- What is Madrigal Pharmaceuticals, Inc.'s operating cash flow?
- -$197.7M over the twelve months to 2026-06-30.
- How much does Madrigal Pharmaceuticals, Inc. spend on capital expenditure?
- $8.6M over the twelve months to 2026-06-30.
- What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
- -$206.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Madrigal Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.